Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the field randomised trial

by Scott, R, Donoghoe, M, Watts, G.F, O'Brien, R, Pardy, C, Taskinen, M.-R, Davis, T.M.E, Colman, P.G, Manning, P, Fulcher, G, Keech, A.C
Published 2020

Role of nicotinic acid in raising high-density lipoprotein cholesterol (HDL-C) to reduce cardiovascular risk: An Asian/Pacific consensus

by Barter, P.J., O'Brien, R., Watts, G.F., Zhu, J., Hu, D., Ho, C.C., Tomlinson, B., Cheung, B.M.-Y., Adam, J.M.F., Tjokroprawiro, A., Waspadji, S., Cho, H.-K., Han, K.-H., Kim, S.-R., Lin, K.K., Chan, S.-P., Basit, A., Pizzaro-Borromeo, A.B., Paz-Pacheco, E., Sy, R.G., Lee, K.O., Low, L.P., Khue, N.T., Binh, T.V.
Published 2011